OpenAI acquires Orchestra Bio to bring AI agents into drug development
OpenAI Group PBC revealed today that it has acquired drug development software startup Orchestra Bio Inc. Orchestra builds artificial intelligence agents that help pharmaceutical teams keep development programs on track,. Its staff and technology will now sit inside OpenAI’s Rosalind life sciences unit. Much of OpenAI’s case for the deal comes down to how long […] The post OpenAI acquires…
OpenAI Group PBC has acquired drug development software startup Orchestra Bio Inc. The company's artificial intelligence agents will now be part of OpenAI's Rosalind life sciences unit. Orchestra Bio's technology helps keep pharmaceutical development programs on track. The deal is aimed at reducing the time it takes for drugs to reach patients, which currently averages 10 to 15 years.
Orchestra Bio's agents monitor studies, manage finances, and address clinical trial scheduling issues. OpenAI claims that the software can assess the impact of a failed manufacturing batch and suggest ways to respond. While scientists will make the final decisions, the combined tools will help them make discoveries and manage the work needed to turn them into treatments.
The terms of the acquisition were not disclosed, and there is no timeline for when Orchestra Bio's agents will be integrated into OpenAI's products. OpenAI's Rosalind business launched in April, and eligible organizations have been able to use it since September. Novo Nordisk A/S and Moderna Inc. are among the drugmakers already utilizing OpenAI's Rosalind.
Written by urgent.news from SiliconANGLE's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
